|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2008-04-22 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2002-11-15 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1996-01-01 |
Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab. in Korean Patients With Acute or Chronic Gastritis in Accordance With Korean Regulation, 'Standard for Re-examination of New Drugs'
This PMS is a non-interventional, prospective, single-arm, multi-center surveillance in accordance with Korean regulation, 'Standard for Re-Examination of New Drugs'. This PMS is to assess the safety and effectiveness after administrating Mucosta®SR Tab. Each subject would be observed for 2 weeks from baseline, if possible. As this PMS is an observational study in practical medical environment, the subject's follow-up is recommended but not obligatory and must be left up to the judgment of the investigator.
A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Phase 3 Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3 study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.
A Randomized, Open Label, Single Dose, Crossover Study to Evaluate the Food Effect on the Pharmacokinetics of "Rebamipide Sustained Release (SR) 150mg" in Healthy Volunteers
This is a randomized, open label, single dose, crossover study to evaluate the food effect on the pharmacokinetics after single oral dose of "rebamipide SR 150 mg" in healthy adult volunteers.
100 项与 Korea Otsuka Pharmaceutical Co., Ltd. 相关的临床结果
0 项与 Korea Otsuka Pharmaceutical Co., Ltd. 相关的专利(医药)
100 项与 Korea Otsuka Pharmaceutical Co., Ltd. 相关的药物交易
100 项与 Korea Otsuka Pharmaceutical Co., Ltd. 相关的转化医学